Liraglutide vs Thymulin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
LiraglutideImmune Support
Thymulin- Summary
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Thymulin is a nonapeptide hormone produced exclusively by the thymic epithelium. It requires zinc for biological activity and plays a critical role in T-lymphocyte maturation, differentiation, and immune regulation. Thymulin levels decline dramatically with age, contributing to immunosenescence.
- Half-Life
- ~13 hours (once-daily dosing)
- ~30 minutes active half-life
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- Start 0.6 mg, titrate to 3 mg
- 20-30 mcg
- Frequency
- Once daily
- 10 days per month (Khavinson protocol)
- Key Benefits
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Enhances T-cell maturation and differentiation
- Boosts NK cell cytotoxic activity
- Reduces inflammatory cytokine production (TNF-α, IL-1)
- Anti-nociceptive (pain-reducing) properties
- Restores age-related immune decline
- Anti-inflammatory via serotonin pathway modulation
- Side Effects
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Injection site reactions
- Mild fatigue initially as immune system activates
- Stacks With
- —
- —